A Study in People With Mild Hypertension
Protocol H8D-MC-EMBH PPAR Alpha (LY518674): a Phase 2 Dose-Response Study to Evaluate the Blood Pressure-Lowering Effect in Essential Hypertension
Sponsor: Eli Lilly and Company
Listed as NCT00374855, this PHASE2 trial focuses on Mild Hypertension and remains completed. Sponsored by Eli Lilly and Company, it has been updated 6 times since 2006, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Sep 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Falköping, Sweden
- • Gothenburg, Sweden
- • Järfälla, Sweden
- • Luleå, Sweden
- • Malmo, Sweden
- • Mönsterås, Sweden
- • Rättvik, Sweden
- • Skellefteå, Sweden
- • Stockholm, Sweden
- • Åmål, Sweden